A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome

BACKGROUND: Hypomethylating agents (HMA), azacitidine, and decitabine are frequently used in the management of myelodysplastic syndromes (MDS). However, there are no clinical trials that have directly compared these agents. We conducted a systematic review and indirectly compared the efficacy of aza...

Descripción completa

Detalles Bibliográficos
Autores principales: Almasri, Jehad, Alkhateeb, Hassan B., Firwana, Belal, Sonbol, Mohamad Bassam, Damlaj, Moussab, Wang, Zhen, Murad, M. Hassan, Al-Kali, Aref
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145118/
https://www.ncbi.nlm.nih.gov/pubmed/30227896
http://dx.doi.org/10.1186/s13643-018-0805-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145118/
https://www.ncbi.nlm.nih.gov/pubmed/30227896
http://dx.doi.org/10.1186/s13643-018-0805-7

Ejemplares similares